Correlation between CYP3A5*3 Gene Polymorphism and Adverse Reactions of Apatinib Monotherapy in Patients with Advanced Gastric Cancer
Objective To investigate the relationship between cytochrome P450 3A5*3(CYP3A5*3)gene polymorphism and adverse reactions of apatinib monotherapy in advanced gastric cancer patients.Methods A total of 86 patients with advanced gastric cancer who received apatinib monotherapy at Nanjing First Hospital from January 2020 to June 2022 were selected,and 2 ml of peripheral venous blood from patients was collected.The genotype of CYP3A5*3 was identified using PCR-RFLP combined sequencing method,and its correlation with adverse reactions was analyzed by apatinib.Results Among the 86 patients,there were 29 cases of mutant heterozygous genotype(AG genotype)and 51 cases of mutant homozygous genotype(GG genotype),with a mutation type accounting for 93.02％.The incidence of hypertension and leukopenia in patients with the CYP3A5*3 GG genotype was significantly higher than in patients with the AA+AG genotype(χ2=6.154,6.947,P=0.043,0.027).Other adverse reactions related to apatinib treatment were not found to be associated with the CYP3A5*3 genotype(P＞0.05).In addition,no correlation was found between severe adverse reactions and the CYP3A5*3 genotype(P＞0.05).Conclusion The CYP3A5*3 GG genotype significantly increased the risk of hypertension and leukopenia caused by apatinib monotherapy,and no correlation was found with the risk of serious adverse reactions.
国家科技期刊平台
NSTL
万方数据
